Who is sponsoring NCT01005771?

NCT01005771 is sponsored by Ferrer Internacional S.A..

What drugs are being tested in NCT01005771?

Interventions in NCT01005771: GF-001001-00, Placebo.

What condition does NCT01005771 study?

NCT01005771 studies Secondarily Infected Traumatic Lesions.

Is NCT01005771 still recruiting?

NCT01005771 is currently completed. Last updated 8 June 2010.

Last reviewed 2010-06-08 · How we verify

NCT01005771

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GF-001001-00 Cream.A Multicentre, Randomised, Double-blind, Parallel, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of 3 Different Doses of GF-001001-00 Cream Versus Placebo Cream Applied 2 Times Daily for 7 Days in the Treatment of Adult Patients With Secondarily-infected Traumatic Lesions

Completed Phase 2 Last updated 8 June 2010

What this trial tests

Phase 2 trial testing GF-001001-00 in Secondarily Infected Traumatic Lesions in 200 participants. Completed in 1 March 2010.

Timeline

1 September 2009

Primary endpoint
1 March 2010

1 March 2010

Quick facts

Lead sponsor	Ferrer Internacional S.A.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	200
Start date	1 September 2009
Primary completion	1 March 2010
Estimated completion	1 March 2010
Sites	1 location across Germany

Drugs / interventions tested

GF-001001-00 — full drug profile →
Placebo

Conditions studied

Secondarily Infected Traumatic Lesions — all drugs for Secondarily Infected Traumatic Lesions →

Sponsor

Ferrer Internacional S.A. — full company profile →

Who can join

18 and older, any sex, with Secondarily Infected Traumatic Lesions. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Clinical cure
Time frame: Day 14

Sponsor's own description

This is a double-blind, randomized, placebo-controlled, parallel-group, dose-finding study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Ferrer Internacional S.A. trials

Trials by the same sponsor.

NCT06499363 — Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Sa · recruiting
NCT05866926 — Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis · Phase 3 · terminated
NCT05178810 — Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Scler · Phase 3 · completed
NCT04065529 — Clinical Trial in Children Between 3 Months and 14 Years Old to Evaluate the Efficacy and Safety of Gelatin Tannate in t · Phase 3 · completed
NCT02525991 — Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01005771 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ferrer Internacional S.A.
Last refreshed: 8 June 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01005771.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing